Skip to main content

Advertisement

Table 6 Comparison of baseline characteristics between TNF-i with MTX (n = 40) and TNF-i without MTX (n = 9)

From: Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease

Variables TNF-i without MTX (n = 9) TNF-i with MTX (n = 40) *P value
Male, n (%) 1 (11.1%) 11 (27.5%) 0.4203
Age (years) 43.7 ± 16.0 40.8 ± 13.7 0.2659
Disease duration (entero-BD, months) 54.0 ± 54.7 52.1 ± 63.5 0.5520
Multiple ulceration, n (%) 5/9 (55.6%) 27/40 (67.5%) 0.7001
History of relapse, n (%) 7/9 (77.8%) 22/40 (55.8%) 0.2771
History of perforation, n (%) 0/9 (0%) 9/40 (22.5%) 0.1795
History of surgery, n (%) 0/9 (0%) 6/40 (15.0%) 0.5765
Concomitant CS use, n (%) 6/9 (66.7%) 23/40 (57.5%) 0.7199
Concomitant CS dose (mg/day) 2.22 ± 3.63 8.83 ± 17.2 0.4414
DAIBD at baseline 61.1 ± 23.3 65.5 ± 37.3 0.8361
  1. Plus-minus values are means ± standard deviation.*P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease